fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      5   |   6   |   7   |   8   |   9   |   10   |   11   |   12   |   13   |   14   |   15      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2010-03-03
Abbott (USA)
GSK (UK)
molecular diagnostic test intended for use as an aid in selecting patients who have MAGE-A3 expressing melanoma tumors.
/ melanoma
R&D
development
See details
2010-03-03
Allergan (USA)
BMS (USA)
AGN-209323
This orally administered small molecule was discovered as part of a collaboration between Allergan and the french biotech company ExonHit Therapeutics SA.
/ neuropathic pain
manufacturing
commercialization/ distribution
development
See details
2010-03-02 Zealand Pharma (Denmark)
PolyTherics (UK)
PEGylated peptides / metabolic, cardiovascular and gastrointestinal diseases R&D
See details
2010-03-02 Metabion (Germany)
Polyplus-Transfection (France)
ZNA™(Zip Nucleic Acids - oligocation-oligonucleotide conjugates that demonstrate an increased affinity for their complementary sequence without reduction in specificity) licensing
See details
2010-03-02 NAICONS scrl (New Anti-Infectives CONSortium -Italy)
Sanofi-Aventis (France)
pre-selected extracts derived for screening against relevant targets from gramnegative pathogens / infectious diseases R&D
See details
2010-03-02 TopoTarget (Denmark)
SpePharm (the Netherlands)
Savene® (desrazoxane - topoisomerase II inhibitor) / prevention of tissue lesions due to accidental extravasation of anthracycline (i.e. leakage of the drug from the blood vessel into which has been injected and where it is supposed to remain) commercialization/ distribution
other
See details
2010-02-25 Evotec(Germany)
Cubist Pharmaceuticals (USA)
fragment-based drug discovery activities on antibacterial targets
/ undisclosed bacterial diseases
R&D
See details
2010-02-25 Regulus Therapeutics (USA)
GSK (UK)
microRNA therapeutics targeting microRNA-122 (miR-122 - liver-expressed microRNA that has been shown to be a critical endogenous “host factor” for the replication of HCV) / Hepatitis C Viral infection R&D
commercialization/ distribution
development
See details
2010-02-24 Zcube (Italy)
QB3/Mission Bay Capital (USA)
  other
See details
2010-02-24 Basilea Pharmaceutica (Switzerland)
Astellas Pharma (Japan)
isavuconazole / invasive fungal infections caused by Aspergillus or other filamentous fungi and Candida fungi licensing
development
marketing/ promotion
See details
2010-02-23 CellCentric (UK)
Takeda Pharmaceutical (Japan)
epigenetic discovery programme / cancer licensing
commercialization/ distribution
development
See details
2010-02-22 GTC Biotherapeutics (USA)
LFB (France)
  other
See details
2010-02-21 NasVax (Israel)
Novartis Vaccines and Diagnostics (Switzerland)
vaccines / influenza R&D
licensing
See details
2010-02-21 Thallion Pharmaceuticals (Canada)
LFB Biotechnologies (France)
Shigamabs® / Shiga toxin-producing E. coli, or STEC, infections commercialization/ distribution
development
See details
2010-02-19 Ark Therapeutics (UK)
Merck &Co (USA)
gene-based medicines manufacturing
See details
[<<]      «      5   |   6   |   7   |   8   |   9   |   10   |   11   |   12   |   13   |   14   |   15      »      [65]